HitGen Future Growth
Future criteria checks 2/6
HitGen is forecast to grow earnings and revenue by 3% and 18% per annum respectively. EPS is expected to grow by 2.9% per annum. Return on equity is forecast to be 4.4% in 3 years.
Key information
3.0%
Earnings growth rate
2.9%
EPS growth rate
Life Sciences earnings growth | 29.8% |
Revenue growth rate | 18.0% |
Future return on equity | 4.4% |
Analyst coverage | Low |
Last updated | 27 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 613 | 76 | 57 | N/A | 2 |
12/31/2025 | 505 | 61 | 42 | N/A | 3 |
12/31/2024 | 436 | 51 | 23 | N/A | 3 |
3/31/2024 | 409 | 67 | N/A | N/A | N/A |
12/31/2023 | 372 | 44 | N/A | N/A | N/A |
9/30/2023 | 357 | 33 | 15 | 125 | N/A |
6/30/2023 | 347 | 38 | -6 | 96 | N/A |
3/31/2023 | 327 | 23 | -31 | 78 | N/A |
12/31/2022 | 330 | 25 | -35 | 53 | N/A |
9/30/2022 | 302 | 44 | -120 | 12 | N/A |
6/30/2022 | 296 | 36 | -126 | 15 | N/A |
3/31/2022 | 314 | 51 | -110 | 24 | N/A |
12/31/2021 | 311 | 63 | -96 | 43 | N/A |
9/30/2021 | 345 | 79 | 14 | 67 | N/A |
6/30/2021 | 311 | 69 | -28 | 43 | N/A |
3/31/2021 | 269 | 61 | -72 | 18 | N/A |
12/31/2020 | 244 | 64 | -81 | 2 | N/A |
9/30/2020 | 235 | 61 | -85 | -16 | N/A |
6/30/2020 | 244 | 76 | 27 | 73 | N/A |
3/31/2020 | 258 | 85 | 85 | 121 | N/A |
12/31/2019 | 264 | 120 | 107 | 168 | N/A |
12/31/2018 | 151 | 45 | -23 | 51 | N/A |
12/31/2017 | 53 | -23 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688222's forecast earnings growth (3% per year) is above the savings rate (2.9%).
Earnings vs Market: 688222's earnings (3% per year) are forecast to grow slower than the CN market (24.4% per year).
High Growth Earnings: 688222's earnings are forecast to grow, but not significantly.
Revenue vs Market: 688222's revenue (18% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 688222's revenue (18% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688222's Return on Equity is forecast to be low in 3 years time (4.4%).